Yes, there is highly effective treatment for HIV/AIDS. Antiretroviral therapy (ART) suppresses the virus to undetectable levels, prevents progression to AIDS, and allows most people to live a near-normal lifespan. While ART is not a cure, it transforms HIV from a fatal diagnosis into a manageable chronic condition. The World Health Organization recommends starting treatment within seven days of diagnosis, with same-day initiation when possible.
How Antiretroviral Therapy Works
HIV replicates by hijacking your immune cells and using their machinery to make copies of itself. Antiretroviral medications interrupt this process at different stages. Some block the virus from entering immune cells in the first place. Others prevent it from copying its genetic material once inside. Still others stop it from assembling new viral particles or transporting key components within the cell. By attacking the virus at multiple points simultaneously, combination therapy makes it extremely difficult for HIV to develop resistance.
A standard regimen typically combines two or three drugs from different classes into a single daily pill. The backbone of most first-line regimens includes a drug that blocks the virus from inserting its genetic code into your DNA, paired with drugs that disrupt its ability to copy itself. Taking these medications consistently drives the amount of virus in your blood down to levels so low that standard tests can’t detect it.
What “Undetectable” Means for Your Health
The goal of treatment is reaching an undetectable viral load, meaning the virus is still present in the body but at levels too low to measure on blood tests. At this point, your immune system can recover and function normally. Life expectancy for people on effective treatment is now only a few years behind that of the general population, according to modeling published in The Lancet HIV.
Reaching undetectable status also eliminates the risk of transmitting HIV to sexual partners. The CDC states this plainly: a person living with HIV who maintains an undetectable viral load has zero risk of sexual transmission. This principle, known as U=U (Undetectable = Untransmittable), has been confirmed in large studies involving thousands of couples where one partner had HIV and the other did not. Not a single transmission occurred when the HIV-positive partner was virally suppressed.
Daily Pills vs. Long-Acting Injections
Most people start treatment with a once-daily pill. But if daily pills are inconvenient or you’d prefer fewer doses, injectable options now exist. Cabenuva is given as an injection every one or two months. Sunlenca requires an injection only every six months. Before switching to injections, you typically take an oral version first for a short period to make sure the medication agrees with your body.
A third injectable option, Trogarzo, is given every two weeks but is reserved for people whose virus has developed resistance to multiple other drug classes. Injectables aren’t yet recommended during pregnancy or breastfeeding due to limited safety data in those situations. If your current daily regimen is working well and you tolerate it without problems, switching isn’t necessary.
Side Effects of Modern Treatment
Today’s medications are far better tolerated than earlier generations, but they aren’t side-effect free. The most commonly discussed issue with current first-line drugs is weight gain. People starting these regimens tend to gain more weight than those on older drug classes, and this effect disproportionately affects women and Black and Hispanic individuals. The exact reasons for this are still being studied.
Some people also experience neuropsychiatric effects like sleep disturbances, insomnia, or changes in mood. Depression and suicidal thoughts have been reported rarely, primarily in people who already had a history of psychiatric illness before starting treatment. Routine blood tests may show a small bump in creatinine (a kidney marker), but this reflects how the drug interacts with the kidney’s filtering process rather than actual kidney damage.
Treatment Is Not a Cure
ART controls HIV but does not eliminate it. The virus hides in a dormant state inside long-lived immune cells, forming what researchers call a latent reservoir. If you stop taking medication, the virus reactivates from these hiding spots and viral load climbs back up, typically within weeks. This is why treatment is lifelong.
True cures have occurred, but only in extraordinary circumstances. Five people (known by the cities where they were treated: Berlin, London, Düsseldorf, New York, and City of Hope) are considered probably cured after receiving bone marrow transplants for cancer. Their donors carried a rare genetic mutation called CCR5-delta 32, which makes cells naturally resistant to HIV. A sixth patient, treated in Geneva, received a transplant from a donor without this mutation and has remained in remission for over 20 months with no detectable virus. These cases are remarkable proof of concept, but bone marrow transplants carry serious risks and are only performed when someone also has a life-threatening cancer. They are not a scalable treatment.
Gene Editing and the Search for a Broader Cure
One of the most closely watched approaches involves using CRISPR gene-editing technology to cut HIV’s genetic code directly out of infected cells. Excision Biotherapeutics completed an early-phase trial using guide molecules that direct a molecular “scissors” to snip the HIV genome at two specific sites, effectively removing it from the cell. The treatment was delivered as a single intravenous infusion.
In May 2024, the company reported that the treatment successfully reached cells throughout the body. However, at the doses tested, it did not function as a cure or allow participants to safely stop their antiretroviral medications. Further testing is currently on hold. The gap between removing virus from some cells and clearing every last reservoir cell in the body remains the central challenge. For now, daily or periodic ART remains the standard of care, and it works remarkably well for the vast majority of people who have access to it.